Medtide Inc.

3880
18.8201.05% ( -0.200 )
Delay Closed: Nov 16, 16:08:00

Overview

Medtide Inc. (3880)

Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and comm...

Open
19.000
High
19.050
Low
18.500
Prev. Close
19.020
Volume
66.00K
Turnover
1.25M
Avg Price
18.880
Bid/Ask Ratio
71.43%
Amplitude
2.89%
52wk High
31.880
Volume Ratio
0.66
Turnover Ratio
0.05%
52wk Low
17.640
HK Mkt Cap
2.67B
Market CapHKD
2.67B
P/ETTM
13.71
P/EDynamic
21.59
P/EStatic
--
EPSTTM
1.37
EPSDynamic
0.872
EPSStatic
--
BVPS
13.29
P/B
1.42
HK Shares
141.80M
Dividend YieldTTM
--
DividendTTM
--
Shares
141.80M
Min lot size
100
Currency
HKD

Medtide Inc. Analyst Rating

View more

Forecast & Rating

Sep 17, 2026
Price forecast
HK$23.0022.19%
Forecast & RatingHold
1analysts
  • Strong buy0.00%
  • Buy0.00%
  • Hold100.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 6

    Medtide fell 0.9% to HK$19.82 in a spike-and-fade session, having touched HK$21.00 at 10:04 BJ (up about 5%) before sliding to a HK$19.71 low late in the afternoon. The swings track project headlines rather than orders: the company signed for industrial land and property in Hangzhou's Qiantang district for phase one of a large-scale CDMO production base, driving a 14.07% gain in a prior week followed by a near-6% single-day drop. Fundamentals remain soft, with Q2 2026 revenue of HK$135.4m down 2.59% yoy, net profit of HK$31.0m down 44.53% and EPS of HK$0.2186 down 51.1%. At HK$19.82 the stock sits below both MA20 (HK$19.92) and MA60 (HK$20.77), down 32.12% YTD and 38.02% below its 52-week high of HK$31.98, while the consensus target was cut 14.81% to HK$23.46. Though with 596 employees, converting capacity into revenue will take time.

  2. Nov, 5

    Medtide opened at HK$19.47, pushed to an intraday HK$20.84 by 11:07 and then faded to close at HK$20.00, up 2.72% on HK$4.28 million turnover and a 0.15% turnover rate. The session extends a two-week run of roughly 6% swings in both directions, with the latest gain sitting alongside the Hangzhou Qiantang industrial land purchase for phase one of its large-scale CDMO base, while executive director Li Lingmei's resignation was disclosed in the same window. Q2 revenue fell 2.59% year on year to HK$135.4 million and net profit dropped 44.53% to HK$31.0 million, EPS at HK$0.2186 down 51.1%, while operating profit declined a narrower 10.85%. At HK$20.00 the stock sits just above its 20-day MA of HK$19.963 but below the 60-day MA of HK$20.801, down 31.51% year to date, 37.46% below the 52-week high of HK$31.98 and 13.38% above the low of HK$17.64, on 14.57x PE, with the consensus target cut to HK$23.46 from HK$27.54. Still, the CDMO capacity has yet to reach the profit line.

  3. Nov, 4

    Medtide rebounded off the lows on Wednesday, slipping to HK$18.89 at 09:47 in the morning session before grinding higher through the afternoon to close near its intraday peak of HK$19.99 at 15:57, up 2.67% from the prior close of HK$19.47 on 225,300 shares, a partial recovery from the previous session's near-6% drop and consistent with progress on the Hangzhou Qiantang industrial land and property acquisition backing its large-scale CDMO production base. The fundamentals cut the other way: Q2 2026 revenue fell 2.59% year on year to HK$135.4 million, net profit dropped 44.53% to HK$31.0 million and EPS halved to HK$0.2186, while the consensus price target was cut 14.81% to HK$23.46. The stock still trades below its MA20 of HK$20.00 and MA60 of HK$20.82, is down 33.32% year to date, sits 39.12% below its 52-week high of HK$31.98 (12 November 2025) and only 10.37% above the 17.64 low of 13 September, while the resignation of executive director Li Lingmei remains to be absorbed.

  4. Nov, 3

    After slumping nearly 6% in the prior session, Medtide traced a volatile rebound on Tuesday, dipping to HK$18.57 at 09:57 before climbing to HK$19.85 at 13:55 and closing at HK$19.47, up 0.52% from the previous close of HK$19.37; the HK$1.28 intraday range equaled roughly 6.6% of that reference price, yet turnover of only HK$4.06 million and a 0.15% turnover rate point to thin participation. The company is proceeding with the acquisition of industrial land and property in Hangzhou's Qiantang District for phase one of a large-scale CDMO production base, a project that had accompanied a 14.07% weekly gain in an earlier update, but Q2 revenue of HK$135.4 million slipped 2.59% year on year, net profit of HK$31.0 million fell 44.53%, and EPS of HK$0.2186 dropped 51.1%, so the expansion story is running against weaker earnings. The consensus price target was lowered 14.81% to HK$23.46 from HK$27.54; at HK$19.47 the stock remains 39.12% below the 52-week high of HK$31.98, down 33.32% YTD, and under both the MA20 of HK$20.059 and MA60 of HK$20.839, leaving the rebound short of a trend reversal.

  5. Oct, 27

    Medtide (3880.HK) spiked then faded, touching HK$21.00 intraday — nearly 7% above the prior close of HK$19.63 — before slipping to HK$19.30 in the afternoon and settling near HK$19.74. The push came from the signed agreement to acquire industrial land and property in Hangzhou's Qiantang District for phase one of its large-scale CDMO production base, with a weekly recap also flagging a 14.07% gain the prior week as capacity-expansion news built. Fundamentals have not kept pace: Q2 2026 revenue of HK$135.4m fell 2.59% y/y, net profit of HK$31.0m dropped 44.53% and EPS of HK$0.2186 was down 51.1%. The stock remains weak on price, down 33.66% year-to-date, about 39.4% below its 52-week high of HK$31.98 and under its MA20 of HK$20.45. The consensus price target was cut 14.81% to HK$23.46. Trading was thin though, with only 86,000 shares changing hands and 0.06% turnover.

News